FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

FDA Approves Rexulti for Treating Agitation Due to Alzheimer's - MyChesCo

Brexpiprazole Demonstrates Clinically Meaningful Improvements for Agitation Due to Alzheimer Disease

FDA Approves First-Ever Drug for Agitation Associated with Alzheimer's Dementia

Articles about Otsuka America Pharmaceutical, Inc.

FDA approves treatment for agitation associated with dementia created by Princeton-based Otsuka

First Treatment for Alzheimer's Agitation Approved by FDA

REXULTI® (brexpiprazole) agitation that may happen with dementia due to Alzheimer's disease

REXULTI® (brexpiprazole), Agitation associated with dementia due to Alzheimer's disease

FDA approves Rexulti for Alzheimer related agitation - News weather sports for Youngstown-Warren Ohio

Mark Oldham on X: I had no clue they were going for this indication! I need to read more about this. #Brexpiprazole is similar to aripiprazole, which is among the most prescribed

Agitation in Alzheimer's: Rexulti® Makes Meaningful Improvements

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation

BXCL501 seen to ease Alzheimer's agitation in Phase 3 trial, Developer BioXcel to meet with FDA to discuss path to approval

FDA panel backs approval of Rexulti for Alzheimer's-related agitation